复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

休市中 09-25 16:08:14

57.200

-0.450

-0.78%

最高60.000	最低56.650	成交量15.93万
今开60.000	昨收57.650	日振幅5.81%
总市值311.74亿	流通市值199.06亿	总股本5.45亿
成交额907.64万	换手率0.05%	流通股本3.48亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":57.2,"timestamp":1790323694003,"preClose":57.65,"halted":0,"volume":159300,"delay":0,"changeRate":-0.007805724197744939,"floatShares":348000000,"shares":545000000,"eps":1.7604730684183691,"marketStatus":"休市中","change":-0.45,"latestTime":"09-25 16:08:14","open":60,"high":60,"low":56.65,"amount":9076446,"amplitude":0.058109,"askPrice":57.2,"askSize":1600,"bidPrice":57.05,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.8419406238440723,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":7,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":57.65,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.15418593024241042,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"1119311542","title":"复宏汉霖2026年中期营收35.88亿元，经调整净利润5.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119311542","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119311542?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:07","pubTimestamp":1790240836,"startTime":"0","endTime":"0","summary":"2026年上半年，复宏汉霖实现营业收入35.88亿元，同比增长27.3%。经调整的净利润为5.72亿元，较上年同期的3.90亿元增长46.7%。公司同期间经营活动现金流约为5.59亿元，同比降低27.4%。报告期内，研发开支约14.51亿元，较上年同期的9.95亿元增长约45.7%，占总营收比重超过四成。管理费用支出约2.48亿元，较上年同期的1.85亿元增长约34%。业务分项上，主要核心产品销售收入增长稳健，其中曲妥珠单抗产品报告期销售额约14.73亿元，叠加许可收入约0.11亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"复宏汉霖2026年中期营收35.88亿元，经调整净利润5.72亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 |  港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","LU0516423174.USD","LU1770034418.SGD","SG9999014674.SGD","LU2328871848.SGD","SG9999002463.SGD","LU0348825331.USD","LU1880383366.USD","688428","LU0456846285.SGD","LU0540923850.HKD","02162","01548","03347","BK1515","LU0348766576.USD","02269","LU1242518931.SGD","LU0348783233.USD","LU1303224171.USD","06990","BK1141","01877","BK1583","KURE","LU1242518857.USD","LU2399975544.HKD","LU2039709279.SGD","LU0828237510.HKD","09995","399441","BK4581","161726","LU0140636845.USD","06160","09926","SG9999002562.SGD","02696","XBI","09969","BK1576","LU0516422366.SGD","LU1961090484.USD","LU0561508036.HKD","HK0000306701.USD","LU0856984785.SGD","LU3063872942.SGD","02268","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122980175","title":"复宏汉霖与Amberstone签署T细胞衔接器全球合作协议 最高对价逾6亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122980175","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122980175?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:02","pubTimestamp":1790154121,"startTime":"0","endTime":"0","summary":"2026年9月23日，上海复宏汉霖生物技术股份有限公司发布自愿性公告称，公司已与Amberstone Biosciences, Inc.签订合作及许可协议，就两款T细胞衔接器产品在全球范围内的研究、开发、生产及商业化展开合作。PCC确定后，复宏汉霖将负责后续的研究、开发、生产及商业化工作。\\n\\n复宏汉霖在公告中提醒，药物研发具有较高的不确定性，合作产品能否最终成功商业化尚存风险，投资者需审慎决策。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669589101","title":"复宏汉霖(02696)就两款T细胞衔接器产品与Amberstone订立的合作及许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2669589101","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669589101?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:00","pubTimestamp":1790154031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，于2026年9月23日，公司与Amberstone Biosciences, Inc.订立一份合作及许可协议，据此，双方同意基于Amberstone专有的T-MATE 技术平台，就两款T细胞衔接器产品用于所有人类用途的全球范围内的研究、开发、生产及商业化作出约定。本次合作有望基于双方在相关领域技术优势和研发能力，共同推进合作产品的研究与开发，有助于进一步丰富公司的创新产品管线，提升公司的持续创新能力和市场竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306685.HKD","HK0000165453.HKD","HK0000320223.HKD","BK1161","HK0000306701.USD","02696","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669935109","title":"复星医药：复宏汉霖获Amberstone授予独家许可，协议包含至多2.36亿美元的总付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2669935109","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669935109?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:38","pubTimestamp":1790152732,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0096","BK0175","BK0012","BK1161","600196","BK1191","BK0188","BK0060","BK1593","HK0000320223.HKD","BK0183","BK0196","HK0000306685.HKD","02696","HK0000306701.USD","HK0000320264.USD","BK1515","BK0187","02196","HK0000165453.HKD","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01877","01548","09969","02268","06990","02269","02162","02359","02696","09926","03347","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669367441","title":"港股异动 | 复宏汉霖(02696)早盘涨超8% 汉达远®于巴基斯坦获批 近期获纳入国家基本药物目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2669367441","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669367441?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:54","pubTimestamp":1789955650,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖早盘涨超8%，截至发稿，涨8.56%，报64.8港元，成交额2010.27万港元。消息面上，近日，据复宏汉霖官微消息，公司宣布，公司商业合作伙伴Getz Pharma  Limited收到相关注册证书，复宏汉霖自主开发和生产的汉达远获得巴基斯坦药监局批准上市，商品名为Adaliget，获批原研阿达木单抗在当地的所有适应症。汉达远已于2026年7月被纳入中国《国家基本药物目录》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498524.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4588","HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD","BK4585","HK0000306685.HKD","BK1161","02696","HK0000320223.HKD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1303224171.USD","KURE","LU0052750758.USD","161726","LU1961090484.USD","LU0516422952.EUR","BK1610","399441","LU0320764243.SGD","BK4588","LU0348766576.USD","LU0128522744.USD","02359","BK1515","LU2488822045.USD","LU2476274720.SGD","02269","LU0463099449.HKD","LU0979878070.USD","LU2045819591.USD","LU0456827905.SGD","LU0196878994.USD","01548","02268","LU0244354667.USD","02696","BK1588","LU0326950275.SGD","06160","LU0029874905.USD","LU2242644610.SGD","LU0320764599.SGD","09926","LU0634319403.HKD","XBI","LU1880383366.USD","LU0348767384.USD","LU0348784397.USD","LU0327786744.USD","06990","02162","09995","LU0561508036.HKD","LU0540923850.HKD","01877","03347","LU1188198961.HKD","09969","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641935","title":"调仓提示！华宝基金港股通创新药ETF（520880）成份股“5进3出”，复宏汉霖等多只新入通标的获纳入","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641935","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667641935?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:10","pubTimestamp":1789470600,"startTime":"0","endTime":"0","summary":"9月14日，100%布局创新药研发龙头的恒生港股通创新药精选指数季度调整正式生效，被动跟踪该指数的港股通创新药ETF华宝同步调仓换血。成份股“5进3出”，总数回升至50只。港股通创新药ETF华宝标的指数相较同类指数率先导入“新鲜血液”：此次调入的5只成份股中，复宏汉霖、和铂医药-B、基石药业-B、瑞博生物-B等4只均为9月7日新纳入港股通的标的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-15/doc-inirxhzq8479614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320223.HKD","HK0000165453.HKD","HK0000306685.HKD","BK1161","159316","HK0000306701.USD","FLHK","02696","520880","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667681787","title":"从“产品出海”到“体系出海”，上海创新药企复宏汉霖加速全球布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2667681787","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667681787?lang=zh_cn&edition=full","pubTime":"2026-09-13 17:19","pubTimestamp":1789291195,"startTime":"0","endTime":"0","summary":"日前，上海创新药企复宏汉霖举办2026年开放日活动，围绕全球化布局、生物类似药商业化、创新研发及临床开发等话题披露最新进展。复宏汉霖执行董事、首席执行官朱俊博士介绍，截至目前，复宏汉霖已有4款产品获美国食品药品监督管理局（FDA）批准、5款获欧盟（EC）批准、8款获中国国家药品监督管理局（NMPA）批准，产品已惠及全球超过110万名患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872844911.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872844911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306701.USD","HK0000320223.HKD","02696","IBBQ","BK1161","HK0000320264.USD","MEDX","LNGR","06978","HK0000165453.HKD","HK0000306685.HKD","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126876650","title":"复宏汉霖HLX14 120mg规格NDA获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1126876650","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126876650?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:41","pubTimestamp":1789116077,"startTime":"0","endTime":"0","summary":"2026年9月11日，上海复宏汉霖生物技术股份有限公司公告，其自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的上市注册申请已获国家药品监督管理局药品审评中心受理。公司表示，该申请基于与参照药的一系列对比数据，包括分析相似性研究、非临床研究和临床研究，结果显示HLX14在质量、安全性与有效性方面与参照药高度相似。2025年12月，该产品60mg/1.0mL规格的NDA已获得国家药监局受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666873547","title":"复宏汉霖(02696.HK)：地舒单抗生物类似药HLX14 120mg(1.7ml)/瓶规格的上市注册申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666873547","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666873547?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:31","pubTimestamp":1789115486,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000165453.HKD","HK0000306685.HKD","HK0000306701.USD","HK0000320223.HKD","02696","HK0000320264.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"对话复宏汉霖朱俊：体系出海要拿“长线收益”，2030年创新药收入将反超生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666356195?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2272731865.HKD","IE00B5TLWC47.USD","HK0000165453.HKD","159992","02696","LU2322448957.HKD","BK1161","LU2473716301.USD","BK1574","IBBQ","HK0000306685.HKD","LU1992135399.USD","LNGR","XPH","MEDX","HK0000306701.USD","HK0000320223.HKD","LU2272731600.USD","BK4585","BK4588","06978","HK0000320264.USD","LU2272731782.SGD","IBB","PPH","LU2322448791.USD","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665391370","title":"复宏汉霖(02696.HK)今日起正式纳入港股通 多重资本利好叠加 全球化商业化步入收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665391370","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665391370?lang=zh_cn&edition=full","pubTime":"2026-09-07 13:37","pubTimestamp":1788759442,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02696","HK0000306701.USD","BK1161","HK0000306685.HKD","HK0000320223.HKD","HK0000165453.HKD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665739964","title":"H股全流通后再迎里程碑，复宏汉霖纳入港股通，流动性与投资者结构持续优化","url":"https://stock-news.laohu8.com/highlight/detail?id=2665739964","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665739964?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:35","pubTimestamp":1788755717,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HK0000165453.HKD","BK1161","HK0000306685.HKD","02696","HK0000306701.USD","HK0000320264.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665396020","title":"复宏汉霖(02696)获纳入港股通标的证券名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2665396020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665396020?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:08","pubTimestamp":1788754101,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，根据上海证券交易所及深圳证券交易所分别发布的《关于沪港通下港股通标的调整的通知》及《关于深港通下的港股通标的证券名单调整的公告》，本公司获调入沪港通与深港通下港股通标的证券名单，自 2026年9月7日起正式生效。沪港通及深港通是香港与中国内地的资本市场投资者之间的股票交易与投资的渠道。本公司被调入沪港通与深港通下港股通标的证券名单，将有助于扩大本公司的股东群体并提升本公司股份的交易流动性，从而进一步提高本公司于资本市场的投资价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","HK0000165453.HKD","161027","HK0000320264.USD","02696","HK0000306685.HKD","FLHK","HK0000306701.USD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179925619","title":"复宏汉霖(02696)被调入沪深港通下港股通股票名单 将于2026年9月7日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1179925619","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179925619?lang=zh_cn&edition=full","pubTime":"2026-09-07 12:06","pubTimestamp":1788753992,"startTime":"0","endTime":"0","summary":"复宏汉霖9月7日公告，公司已被上海证券交易所与深圳证券交易所分别发布的《关于沪港通下港股通标的调整的通知》及《关于深港通下的港股通标的证券名单调整的公告》纳入港股通标的证券名单，相关调整自2026年9月7日起正式生效。公司表示，获纳入沪港通及深港通下港股通标的后，将有助于扩大股东群体并提升公司股份交易流动性，进一步提高在资本市场的投资价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665363260","title":"对话复宏汉霖朱俊：AI不只是效率工具，还将成为重塑新药研发的决定性力量","url":"https://stock-news.laohu8.com/highlight/detail?id=2665363260","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665363260?lang=zh_cn&edition=full","pubTime":"2026-09-05 22:55","pubTimestamp":1788620100,"startTime":"0","endTime":"0","summary":"在AI对新药研发的影响方面，朱俊认为，AI不止能缩短研发周期，还能够成为新药研发的决定性力量。在竞争格局层面，朱俊认为AI将改变中国药企“靠体量获胜”的盈利模式。此外，朱俊还分享了AI在实际管线中的应用。公司一款减肥针剂资产，对标产品“能增肌减肥但亲和力低、要求剂量高，导致痤疮、肌痉挛等副作用”，而复宏汉霖通过AI找到相应表位，使亲和力提升20倍以上，副作用大幅减少。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-05/doc-iniquyin4906948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AIPO","QTOC","HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD","VTHR","ARTY","HK0000306685.HKD","BK1161","CHAT","02696","HK0000320223.HKD","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"复宏汉霖朱俊：未来所有制药企业都是AI制药企业，不存在不依赖AI的生物制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665936888?lang=zh_cn&edition=full","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320264.USD","MRNX","HK0000306701.USD","VTHR","AIPO","BK1574","CHAT","HK0000165453.HKD","BK1161","IBBQ","HK0000306685.HKD","02696","03069","01477","BK1191","BBP","QTOC","HK0000320223.HKD","ARTY","AGIX","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158076719","title":"复宏汉霖更新2026年8月股份变动月报表，注册股本增至5.45亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1158076719","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158076719?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:43","pubTimestamp":1788342192,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年9月2日披露2026年8月股份变动月报。报告期为2026年8月1日至8月31日，注册股本由原先的人民币34.78亿股和对应金额，增加5.28万股至人民币5.45亿股。同期失效购股权5.44万股，失效受限制股份单位5.44万份。截至报告期末，普通股H股总数约为3.48亿股，其他类别非上市股份保持1.97亿股不变。本月内公司未发生股份回购、注销或库藏股相关活动。本月报由董事Wenjie ZHANG签署并提交。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0419},{"period":"1month","weight":-0.1625},{"period":"3month","weight":0.0306},{"period":"6month","weight":-0.2022},{"period":"1year","weight":-0.2286},{"period":"ytd","weight":0.0026}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.008815},{"month":4,"riseRate":0.857143,"avgChangeRate":0.12138},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.033714},{"month":6,"riseRate":0.571429,"avgChangeRate":0.085211},{"month":7,"riseRate":0.428571,"avgChangeRate":0.040127},{"month":8,"riseRate":0.571429,"avgChangeRate":0.005816},{"month":9,"riseRate":0,"avgChangeRate":-0.128277},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}